DTL News

Posted by: Dave Fox
<  Back to news page

Jon Heylings retirement – 31st March 2021

As Dermal Technology Laboratory Ltd enters its 15th year of operation, one of our founders, Professor Jon Heylings has decided to retire as Chairman of DTL.

Following the Syngenta announcement, in late 2006, that their Central Toxicology Laboratory was closing down, Jon and I activated my plan to form our own business and build on the client base and reputation Jon’s team had built in the field of in vitro dermal absorption since the early 1990s.

Making the leap from employees to business owners, we took our opportunity in 2007 to form DTL.  Under Jon’s scientific leadership, DTL continued to provide both regulatory studies and research to our expanding range of international clients.

After his retirement from DTL, Jon will be continuing his other scientific roles, including assistance with OECD on in vitro dermal absorption guidelines and he retains his role as Honorary Professor of Toxicology at Keele University.

I, along with all the team at DTL, wish Jon all the best in his retirement and thank him for his time building DTL to the successful business it is today.

Although Jon is no longer a part of our organisation, DTL will continue to have the option to draw on Jon’s wealth of knowledge in our field.

Moving forward, DTL has partnered with Dr Clive Roper (formerly of Charles River) for continued support and consultancy.

The remaining team at DTL and I look forward to entering a new phase for the business, and, as we look forward, we will be forming new alliances with other prominent scientists and organisations in the in vitro dermal arena.

Dave Fox

Managing Director, DTL